Ποια είναι η τιμή για Pascal Biosciences Inc. (PSCBF)

Η τιμή για Pascal Biosciences Inc. (PSCBF) είναι $0.1

Ποια είναι η κεφαλαιοποίηση αγοράς για Pascal Biosciences Inc. (PSCBF)

Η κεφαλαιοποίηση αγοράς για Pascal Biosciences Inc. (PSCBF) είναι $1.31M

Pascal Biosciences Inc. (PSCBF) Έσοδα

Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to discovering and advancing therapeutic solutions for oncology and bolstering immune system function. The company's robust pipeline includes several key candidates: PAS-403, a potent mitosis inhibitor designed to impede cancerous cell division, specifically targeting glioblastoma and secondary brain tumors; and PAS-393, an immunomodulatory cannabinoid developed to enhance the immune system's recognition of tumor cells when utilized alongside checkpoint inhibitor therapy. Furthermore, Pascal is progressing a specialized antibody therapy aimed at B-cells, intended for conditions like acute lymphoblastic leukemia and various B-cell lymphomas. The company is also investigating cannabinoid-derived products as potential treatments for COVID-19. To support its research, Pascal Biosciences maintains an exclusive licensing agreement with the University of Washington for a cannabinoid-based therapeutic against glioblastoma multiforme and brain metastases. It also benefits from a collaborative research partnership with SoRSE Technology Corporation, focused on advancing PAS-393 toward clinical trials. Founded in 2011, the company operates from its headquarters in Seattle, Washington.

Έτος	Έσοδα	Αλλαγή
2026 (TTM)	$700.83K	41.81%
2023	$494.20K	0.00%
2022	0.00	0.00%
2021	0.00	0.00%
2020	0.00	0.00%
2019	0.00	0.00%

Έτος

Έσοδα

Αλλαγή

2026 (TTM)

$700.83K

41.81%

2023

$494.20K

0.00%

2022

0.00

0.00%

2021

0.00

0.00%

2020

0.00

0.00%

2019

0.00

0.00%

Εταιρεία	Έσοδα	Διαφορά Εσόδων	Χώρα
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	1,801,231.33%	US
Argenx SE ARGX.US	$6.02B	859,063.16%	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$10.11B	1,442,584.10%	BE

Εταιρεία

Έσοδα

Διαφορά Εσόδων

Χώρα